Amunix Raises $73 Million in Series A Financing Led by Omega Funds

BioSpace | March 04, 2020

Amunix Pharmaceuticals Inc.  (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock, and Delian Capital.

Spotlight

As you head off to the beach this summer with your family and friends, biotechnology is probably the last thing on your mind. What you might not realize is the vast amount of potential that the world's oceans hold for curing disease.

Spotlight

As you head off to the beach this summer with your family and friends, biotechnology is probably the last thing on your mind. What you might not realize is the vast amount of potential that the world's oceans hold for curing disease.

Related News

MEDTECH

Avantor® will Increase Global Production of Single-Use Technologies to Meet the Biopharma Demand

Avantor | April 27, 2021

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation will uphold developing client interest for monoclonal antibodies (mAbs), novel cell and quality treatments for oncology and different illnesses, just as immunizations, including those for COVID-19. Avantor as of late extended its Morrisville, North Carolina, single-use office and expects finish of a cleanroom extension at its Devens, Massachusetts, activity by mid-year. The Company likewise hopes to open its subsequent European single-use office in Hillegom, the Netherlands, by then too. Dr. Ger Brophy, Executive Vice President of Biopharma Production at Avantor, said, "The business' reaction to the COVID-19 pandemic has depended intensely on the incorporation of single-use items into biopharma creation measures. Adequacy and security are critical to our clients, and they look to us to comprehend and uphold their prerequisites as they quickly extend their assembling limit. "These options to our worldwide single-use fabricating biological system are basic strides in empowering our clients to get treatments to patients rapidly," Brophy added. The speculation further fortifies the Company's single-use organization, giving item consistency and abilities near bioproduction clients to help guarantee productive and continuous stock. About Avantor Avantor®, a Fortune 500 organization, is a main worldwide supplier of strategic items and administrations to clients in biopharma, medical care, training and government, and trendsetting innovations and applied materials enterprises. Our portfolio is utilized in essentially every phase of the main examination, advancement, and creation exercises in the enterprises we serve. Our worldwide impression empowers us to serve more than 225,000 client areas and gives us broad admittance to explore research facilities and researchers over 180 nations. We set science underway to make a superior world.

Read More

MEDICAL

Controlant now Providing Monitoring and Supply Chain Visibility for Pfizer-BioNTech COVID-19 Vaccine's Global Distribution

Controlant | December 16, 2020

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant is providing to Pfizer to mRNA-based Pfizer-BioNTech COVID-19 vaccine distribution supply chain, the organization is likewise working straightforwardly with the U.S. Government and wellbeing authorities, for example, the Center for Disease Control (CDC), U.S. Division of Health and Human Services (HHS), and stakeholders in Operation Warp Speed, to give nearby observing at U.S. Government-preferred designated vaccination areas to help consistently guarantee coherence during hand-off, actionable communication, and visibility, all through the entirety of the U.S. supply chain journey of the vaccines.

Read More

DIAGNOSTICS

Avantor® to Collaborate with GeminiBio to Bring Custom Hydrated Solutions and Cell Culture Media to Biopharma Customers

Avantor | June 24, 2022

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries has entered into an agreement with GeminiBio to deliver custom hydrated solutions and cell culture media to the biopharma industry. Custom hydrated solutions and cell culture media are critical components of the bioproduction workflow, especially for emerging modalities such as gene therapy. This collaboration will complement Avantor's proven ability to serve manufacturing platforms with GeminiBio's small-to-medium scale offering, enabling customers to utilize custom cGMP products through the full development lifecycle – including early-stage research, scale-up and commercialization. This new capability along with Avantor's recent acquisitions and site investments, support a growing portfolio of proprietary offerings, demonstrating Avantor's commitment to supporting customer workflows in both upstream and downstream processing for the biopharma industry. With the imperative to meet patient needs quickly, our customers require custom solutions to accelerate their bioproduction goals, Customized media is critical in optimizing cell line productivity, and hydrated solutions offer efficiency to biomanufacturers as they optimize their downstream processes. Our collaboration with GeminiBio will drive increases in product yields, helping bring efficiency and speed to our customers as they scale. Together, we can drive science forward to bring therapies to the patients who need them most." Dr. Ger Brophy, Executive Vice President, Biopharma Production for Avantor. Enabling customers to optimize their upstream and downstream liquid manufacturing workflows by offering custom solutions, built around a strong quality foundation, has been an essential part of GeminiBio's success. Collaborating with Avantor, who shares our focus on quality, will allow us to expand our ability to address customer needs for both small and large volume process liquids." Brian Parker, CEO of GeminiBio. About Avantor Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.

Read More